Phase III, Multi-centre, Ransomised Controlled Study of Sonesitatug vedotin in Combination with Fluoropyrimidine with or without Rilvegostomig in First-line Claudin 18.2-positive HER2-negative Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma